Abstracts tagged "Disease Activity"

Abstract Number: 418 • 2014 ACR/ARHP Annual Meeting
Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients
Vibeke Strand¹, Robert J. Holt², Katherine C. Saunders³, Jeffery D. Kent⁴, Ping Xu⁵, Amy Y. Grahn⁴, Marc Mason³ and Carol J. Etzel^6,7, ¹Stanford University, Palo Alto, CA, ²University of Illinois - Chicago, Chicago, IL, ³Corrona, LLC., Southborough, MA, ⁴Horizon Pharma, Inc., Deerfield, IL, ⁵Axio Research LLC, Seattle, WA, ⁶PO Box 786, Corrona, LLC., Southborough, MA, ⁷Department of Epidemiology, UT MD Anderson, Houston, TX
Background/Purpose : Morning stiffness is a symptom of rheumatoid arthritis (RA) that is frequently reported and thought to reflect disease activity, but its etiology is…
Abstract Number: 258 • 2014 ACR/ARHP Annual Meeting
Pain Characteristics Among Patients with Rheumatoid Arthritis in the Context of Patient-Physician Discordance in Disease Activity Assessments
John M. Davis III¹, Cynthia S. Crowson², Tim Bongartz¹, Clement J. Michet¹, Eric L. Matteson¹ and Sherine E. Gabriel³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Healthcare must be patient-centered to achieve optimal outcomes and quality of life. From this perspective, it is significant that patients with rheumatoid arthritis (RA)…
Abstract Number: 2822 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
Edward C. Keystone¹, Peter C. Taylor², Mark C Genovese³, Douglas E. Schlichting⁴, Inmaculada De La Torre⁵, Scott D. Beattie⁴ and Terence Rooney⁴, ¹University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵AVDA. DE LA INDUSTRIA 30, Eli Lilly and Company, Alcobendas, Spain
Background/Purpose: Baricitinib is an oral inhibitor of JAK1/JAK2 being investigated as a treatment for rheumatoid arthritis (RA). In a phase 2b study, baricitinib treatment resulted…
Abstract Number: 2488 • 2014 ACR/ARHP Annual Meeting
Relationship Between Different Clinical Measurements and Patient-Reported Outcomes
Roy Fleischmann¹, V Strand², B Wilkinson³, K Kwok⁴ and E Bananis³, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, ²Biopharmaceutical Consultant, Portola Valley, CA, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the relationship between clinical measures and patient-reported…
Abstract Number: 1937 • 2014 ACR/ARHP Annual Meeting
Model Examining Factors Related to Physicians’ Ratings of Disease Activity in Patients with RA
Julia R. Ayeroff¹, Sarah R. Ormseth², David Hardy³, Michael R. Irwin², Michael H. Weisman⁴ and Perry M. Nicassio², ¹Postbaccalaureate Premedical Program, University of Southern California, Los Angeles, CA, ²Cousins Center for PNI, University of California, Los Angeles, Los Angeles, CA, ³Psychology, Loyola Marymount University, Los Angeles, CA, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: The purpose of this study was to examine a multidimensional, integrated model describing the interrelations among rheumatoid arthritis (RA) objective disease activity, patient-rated disease…
Abstract Number: 1489 • 2014 ACR/ARHP Annual Meeting
Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis –a Multicenter Registry Study-
Yuji Hirano¹, Toshihisa Kojima², Yasuhide Kanayama³, Shinya Hirabara¹, Nobunori Takahashi², Atsushi Kaneko⁴ and Naoki Ishiguro², ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan
Background/Purpose: Iguratimod (IGU), known as T-614, is a small-molecule antirheumatic drug developed in Japan and used in Japanese clinical practice since June in 2012. IGU…
Abstract Number: 1054 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis
Daniel Aletaha¹, Farideh Alasti² and Josef Smolen³, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose To investigate the associations of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA) with rheumatoid arthritis (RA) disease activity.Methods We analyzed the association…
Abstract Number: 711 • 2014 ACR/ARHP Annual Meeting
Is the Disease-Specific Lupusqol Sensitive to Changes of Disease Activity in SLE Patients after Treatment of a Flare?
Kathleen McElhone¹, Jane Burnell², Chris Sutton², Janice Abbott³, Peter Lanyon⁴, Anisur Rahman⁵, Chee-Seng Yee⁶, Mohammed Akil⁷, Yasmeen Ahmad⁸, Ian Bruce⁹, Caroline Gordon¹⁰ and Lee-Suan Teh¹¹, ¹Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom, ²School of Health, University of Central Lancashire, Preston, United Kingdom, ³University of Central Lancashire, Preston, United Kingdom, ⁴Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁵Centre for Rheumatology Research, University College London, London, United Kingdom, ⁶Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ⁷Sheffield Center Rheumatic Dis, Sheffield South Yorkshire, United Kingdom, ⁸Department of Rheumatology, Peter Maddison Research Centre, Bangor, United Kingdom, ⁹Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ¹⁰Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹¹Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom
Background/Purpose With improving survival in SLE patients, patient-reported health-related quality of life (HRQoL) has become an important outcome. The LupusQoL is a disease-specific patient-derived HRQoL measure…
Abstract Number: 416 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient-Derived Versions of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28 (DAS28)
Erin Carruthers¹, Noura AL Osaimi², Charles H Goldsmith³, Paul Adam⁴ and Diane Lacaille⁵, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient self- monitoring of disease activity may enhance treatment by providing early…
Abstract Number: 271 • 2014 ACR/ARHP Annual Meeting
Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Lianne Kearsley-Fleet¹, Rebecca Davies¹, Mark Lunt¹, Taunton R. Southwood², Kimme L. Hyrich³ and on Behalf Of The BSPAR Etanercept Cohort Study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Etanercept (ETN) is licensed in Europe for use in children with Juvenile Idiopathic Arthritis (JIA) and is routinely prescribed after failure of other DMARDs.…
Abstract Number: 2241 • 2013 ACR/ARHP Annual Meeting
Assessing Significant Flares In Rheumatoid Arthritis: Validity Of The Outcome Measures In Rheumatology Preliminary Flare Questions In The Canadian Early Arthritis Cohort
Susan J. Bartlett^1,2, Clifton O. Bingham III³, Ernest Choy⁴, Juan Xiong⁵, Gilles Boire⁶, Boulos Haraoui⁷, Janet E. Pope^8,9, J. Carter Thorne¹⁰, Carol A. Hitchon¹¹, Diane Tin¹², Edward C. Keystone¹³ and Vivian P. Bykerk^13,14, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ⁵Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁸St Joseph Health Care, London, ON, Canada, ⁹Univ of Western Ontario, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ¹⁴Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) flares are common, poorly defined, and understudied. A tool is needed to measure significant RA flares that may signal need for…
Abstract Number: 1667 • 2013 ACR/ARHP Annual Meeting
Serum S100A8/S100A9 and S100A12 As a Marker Of Disease Activity In Giant Cell Arteritis
Jason Springer¹, Dirk Holzinger², Gary S. Hoffman³, Paul A. Monach⁴, Thomas Hamilton⁵, Carol A. Langford⁶, Dirk Foell⁷, David Cuthbertson⁸, Colin O'Rourke⁹, Simon Carette¹⁰, Nader A. Khalidi¹¹, Carol McAlear¹², Christian Pagnoux¹⁰, Philip Seo¹³, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁵, Thomas Vogl¹⁶, Peter A. Merkel¹⁷, Johannes Roth¹⁸ and Rula Hajj-Ali¹⁹, ¹Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Institute of Immunology, University Muenster, Muenster, Germany, ³Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁴Rheumatology, Boston University, Boston, MA, ⁵Cleveland Clinic, Cleveland, OH, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Department of Pediatric Rheumatology and Immunology, University of Münster, Münster, Germany, ⁸Department of Biostatistics, University of South Florida, Tampa, FL, ⁹Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ¹⁰Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹¹Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶Institute of Immunology, University of Muenster, Muenster, Germany, ¹⁷Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁸Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ¹⁹Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: The S100 proteins (S100A8/9 complex and S100A12) are calcium binding proteins expressed during myeloid differentiation. S100 proteins are phagocyte-specific proteins that have been demonstrated…
Abstract Number: 1341 • 2013 ACR/ARHP Annual Meeting
Significantly Less Glucocorticoids and Better Patient-Reported Outcomes In Women With Early Inflammatory Arthritis Using Oral Contraceptives Compared To Never Users
Gisela Westhoff¹, Rainer H. Straub², Frank Buttgereit³, Johanna Callhoff⁴ and Angela Zink⁵, ¹Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany, ²Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴German Rheumatism Research Center, Berlin, Germany, ⁵German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Data on the effects of oral contraceptives (OC) on the course of inflammatory arthritis (IA) are controversial. However, a recent analysis of data from…
Abstract Number: 792 • 2013 ACR/ARHP Annual Meeting
Methotrexate Polyglutamates in Erythrocytes Are Associated With Lower Disease Activity in Juvenile Idiopathic Arthritis Patients
Maja Bulatovic Calasan¹, Ethan den Boer², Maurits C.F.J. De Rotte³, S.J. Vastert⁴, Sylvia Kamphuis⁵, Robert De Jonge³ and Nico M. Wulffraat⁶, ¹Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands, ³Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁶Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Methotrexate polyglutamates (MTX-PG) could be biomarkers of MTX response and adverse effects and could thus be used as a therapeutic drug monitoring (TDM) tool to steer tailor-made therapeutic…
Abstract Number: 306 • 2013 ACR/ARHP Annual Meeting
Responsiveness To Change Of a Global Ultrasound Assessment Score In Psoriatic Arthritis Patients
Maria Laura Acosta Felquer¹, Santiago Ruta¹, Javier Rosa², David A. Navarta³, Carla Saucedo¹, Ricardo Garcia-Monaco⁴, Mirtha Sabelli² and Enrique R. Soriano⁵, ¹Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina
Background/Purpose: Psoriatic arthritis (PsA) manifests clinically in several ways, including arthritis, enthesitis, and dactylitis,. Assessment of disease activity in PsA should ideally record each feature.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].